In a strategic move to reinforce its position in the fast-growing healthcare logistics sector, DHL Group has announced a major expansion of its dedicated airfreight cold chain network. The initiative forms part of the Group’s €2 billion (₹213.82 billion) investment into its DHL Health Logistics division, aimed at strengthening infrastructure for the secure, compliant, and temperature-controlled transportation of sensitive pharmaceutical and life sciences products worldwide.
The expansion reflects a decisive shift in DHL’s operating model. Rather than relying predominantly on third-party commercial airline capacity, the company is increasing the use of dedicated freighter aircraft and controlled aviation hubs. This strategic realignment allows DHL to exercise tighter control over transit times, handling procedures, and temperature compliance critical factors in the transportation of biologics, advanced vaccines, clinical trial materials, and increasingly complex cell and gene therapies.
Expanding into key pharmaceutical trade corridors
The enhanced cold chain airfreight network will be extended across several high-growth pharmaceutical markets, including India, Singapore, Japan, South Korea, Brazil, the United States, Germany, and Ireland. These countries represent vital production and consumption nodes within the global life sciences supply chain, and strengthening connectivity between them is central to ensuring supply continuity and regulatory compliance.
India, in particular, plays a pivotal role in global pharmaceutical manufacturing, accounting for a significant share of vaccine production and generic drug exports. Strengthening cold chain airfreight connectivity to and from India is expected to support the country’s growing
biologics and specialty medicines segment, while enhancing its integration with North American and European markets.
Dedicated freighter corridor between Europe and the United States
A cornerstone of the expansion is the introduction of a dedicated Boeing 777F service linking Brussels Airport (BRU) with Cincinnati/Northern Kentucky International Airport (CVG). This new trade lane establishes a high-capacity, temperature-controlled air corridor connecting Europe’s leading pharmaceutical cluster with the U.S. Midwest a region widely recognized as a global centre for biopharmaceutical manufacturing.
By routing shipments directly between inland hubs and bypassing congested coastal gateways, the BRU–CVG service enhances schedule reliability and minimises temperature excursion risks. For time-critical therapies, particularly advanced biologics and personalised medicines, such reliability is increasingly non-negotiable. The Brussels hub is supported by 45,000 square metres of dedicated pharmaceutical handling infrastructure at BRUcargo, including controlled temperature zones, validated storage areas, and specialised handling procedures aligned with Good Distribution Practice (GDP) standards. This facility is widely regarded as one of the most advanced pharma airfreight gateways in Europe.
Responding to structural changes in healthcare supply chains
The expansion comes at a time when pharmaceutical supply chains are undergoing structural transformation. The rapid development of mRNA vaccines, cell therapies, biologics, and temperature-sensitive injectables has significantly increased demand for validated cold chain logistics capable of maintaining strict temperature bands ranging from controlled ambient conditions to ultra-low frozen environments. Oscar de Bok, CEO of DHL Global Forwarding, Freight, stated that life sciences and healthcare companies are demanding higher levels of reliability, compliance, and transparency across the supply chain. He emphasised that DHL’s investment aims to create a more resilient logistics backbone that can withstand geopolitical uncertainty, capacity shortages, and market volatility while maintaining product integrity.
